Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898810 | 1.00 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL6214741 | 0.89 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL4707157 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL13305932 | 0.88 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL13774927 | 0.88 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL22468533 | 0.85 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL28517383 | 0.85 | HCAR2 (0.47) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL567435 | 0.82 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL10885861 | 0.81 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL6538869 | 0.80 | MEN1 (0.63) | MEN1KMT2ASMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903004-A | Synthesis method of Fmoc-a-methyl-L-glutamic acid (5-tert-butyl ester) | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117903004-A | Synthesis method of Fmoc-a-methyl-L-glutamic acid (5-tert-butyl ester) | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903004-A | Synthesis method of Fmoc-a-methyl-L-glutamic acid (5-tert-butyl ester) | 康化（上海）新药研发有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-7652007-B2 | Obesity, type II diabetes; such as 6-(4-Chlorobenzyl)-1-(2,4-dichlorobenzenesulfonyl)-8-isopropylhexahydropyrazino[1,2-a]pyrimidine-4,7-dione | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-26 | — | — | US | disclosed |
| EP-1597259-B1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | MEN1 1919/4885KMT2A 4297/4885SMN1; SMN2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.